Stock SGMO SANGAMO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
0.4548 USD +3.74% Intraday chart for Sangamo Therapeutics, Inc. +41.02% -16.29%
May. 14 Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
May. 09 Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA
AQ
Transcript : Sangamo Therapeutics, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 08:30 AM
Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Sangamo: Q1 Earnings Snapshot
AQ
Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000
MT
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
BU
Sangamo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sangamo Therapeutics, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2024
CI
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
BU
Sangamo Therapeutics : ASGCT 2024
PU
Sangamo Therapeutics : Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MINTS)
PU
Sangamo Therapeutics : Widespread CNS Tau Knockdown for the Potential Treatment of Alzheimer’s Disease and other Tauopathies
PU
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
BU
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting
AQ
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
BU
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
AQ
Sangamo Therapeutics Prices $24 Million Registered Direct Offering
MT
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
BU
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says
MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGMO Stock
  4. News Sangamo Therapeutics, Inc.